Topic: clinical trial data
Neither dose of the NGF inhibitor hit all the co-primary efficacy goals, and both fared worse than placebo on the safety assessments.
Mustang Bio’s stock leapt more than 400% before settling down, on the news that its gene therapy cured eight infants with “bubble boy” syndrome.
The breakthrough tag comes as Genfit gears up to start a phase 3 trial in the indication later in the year.
The phase 1 trial linked the drug to a 45% response rate in a subpopulation of solid tumor patients resistant or intolerant to a prior TRK inhibitor.
The trial linked the antibody-drug conjugate to a 44% response rate in patients with locally advanced or metastatic urothelial cancer.
Patients taking GlaxoSmithKline’s anti-BCMA treatment for multiple myeloma had an overall response rate of 60% and median progression-free survival of one year, new phase 1 data show.
The drug failed to clearly outperform a generic used as a control, leaving room to doubt whether vibegron poses a big threat to Astellas’ Myrbetriq.
Phase 1 data for PhaseBio's Brilinta reversal agent showed the drug quickly reversed the effects of Brilinta without causing serious side effects.
Syndax’s entinostat missed its primary endpoints in two phase 1b/2 trials combining it with anti-PD-1 drugs from Genentech and Merck KGaA and Pfizer.
Rapastinel, the depression drug that Allergan picked up in its $560 million Naurex acquisition, missed its primary endpoint in three pivotal trials.